Latent Tuberculosis Infection among Health Workers in Germany—A Retrospective Study on Progression Risk and Use of Preventive Therapy

Nika Zielinski 1, Johanna Stranzinger 2, Hajo Zeeb 1-3*, Jan Felix Kersten 4 and Albert Nienhaus 2,4,*

Abstract: Despite the decline in tuberculosis incidence (TB) in Germany, health workers (HW) are at greater risk of becoming infected with Mycobacterium tuberculosis. To date, little is known about the risk of progression of latent tuberculosis infections (LTBI) and the use of Tuberculosis Preventive Therapy (TPT) among HW. Routine data from the German Statutory Institution for Accident Insurance and Prevention for Health and Welfare Services (BGW) were analysed and a retrospective survey was conducted. A self-administered questionnaire was sent to 1711 HW who had received recognition of an LTBI as an occupational disease between the years 2009 and 2018. The response rate was 42.3% after correcting for those with no actual address (20.4%). We included 575 HW in the data analysis of the retrospective survey. The cumulative incidence of progression, the incidence density and the associated 95% confidence interval (95% CI) were calculated. Three progressive cases were identified in the analysis of the routine data. In the survey cohort, three HW developed TB during the observation period of 5.4 years on average (standard deviation: 2.8 years; interquartile range: 5.0 years). The cumulative TB incidence was 0.52% in the survey group (95% CI: 0.25 to 3.10). One-third of the respondents underwent TPT. Significant differences were observed between age and activity groups in the use of TPT, but not between the genders, year of diagnosis or the reason for performing the screening. The data indicate that the risk of progression of an LTBI is low for HW. However, one-third of the HW had undergone TPT. Information about the expected progression risk is important so that it can be weighed against the risk of side effects of TPT.

Keywords: latent tuberculosis infection (LTBI); progression; Tuberculosis Preventive Therapy (TPT); health workers; occupational health

1. Introduction

Health workers (HW) are at greater risk of infection compared to non-medical occupational groups due to their occupational exposure to tuberculosis (TB) [1]. In Germany, the prevalence of Latent TB Infection (LTBI) among health workers is estimated to be around 10% based on examinations conducted in connection with preventative occupational medicine [2,3]. TB infections and illnesses of occupational origin may be recognised as occupational diseases in workers in healthcare, welfare, laboratories or in positions where there is an elevated risk of infection [4]. For the German Statutory Institution for Accident Insurance and Prevention for Health and Welfare Services (BGW), around half of

all recognised occupational diseases caused by infection (BK 3101) are attributable to LTBI and TB cases [5].

COVID-19 and TB are both airborne diseases. As the infection-risk of HW for TB is well established, there can be lessons learnt from TB prevention for COVID-19 prevention. However, it needs to be emphasised that the number of HW with COVID-19 is much higher than the number of HW with LTBI as an occupational disease. In Germany, during the last 13 months, more than 50,000 occupational diseases because of COVID-19 were recognised, while about 200 occupational diseases because of LTBI are recognised every year.

After infection with Mycobacterium tuberculosis, it is possible that the disease may progress to active TB, requiring treatment. According to estimates of the World Health Organization (WHO), 5 to 10% of infected adults have an LTBI that progresses to active TB during lifetime [6]. The LTBI may be treated with Tuberculosis Preventive Therapy (TPT) to potentially reduce the risk of progression by up to 90% [7]. TPT aims to eliminate bacteria during its dormant (“inactive”) state [8]. It is necessary to keep the progression rate among HW low in the interest of infection and patient safety [9].

Little is known about the progression risk of LTBI among HW to date. In Germany, no cases with progression were found among HW in two studies [10,11]. However, these studies did not systematically examine progression risk. In Portugal, a progression rate among HW of 0.4% was found in two years [12]. No studies could be found on the use of TPT among HW in Germany. This study aims to gain new insights into the progression rate among HW and to estimate how many undergo TPT.

2. Materials and Methods

The analysis is based on a routine dataset from BGW, which includes all LTBI occupational disease cases recognised from 2009 until 2018. A total of 1711 cases of occupational-related LTBI were recognised in this time period (Table 1), which are on average 171 cases per year with no obvious time trend. To estimate progression rates among health workers, two strategies were pursued.

Table 1. Recognised occupational latent tuberculosis infections (LTBI). Data from the German Statutory Institution for Accident Insurance and Prevention for Health and Welfare Services (BGW) for 2009 to 2018 (n = 1711).

| Year   | Number of LTBI Recognitions |
|--------|-----------------------------|
| 2009   | 67                          |
| 2010   | 126                         |
| 2011   | 171                         |
| 2012   | 181                         |
| 2013   | 241                         |
| 2014   | 204                         |
| 2015   | 180                         |
| 2016   | 159                         |
| 2017   | 202                         |
| 2018   | 180                         |
| Total  | 1711                        |

First, BGW’s routine data were examined for progressive cases. This involved pairing LTBI and TB cases using personal identification numbers for all recognised occupational diseases arising from an LTBI between 2009 and 2018. This enabled the identification of insured patients for whom an LTBI had first been reported and subsequently a second file had been opened for TB as an occupational disease. A case file analysis was conducted of high-cost LTBI cases, because it is also possible for the TB to be registered in connection
with a previously recognised occupational disease (in this case LTBI). In 2012, Diel et al. [13] calculated the average direct costs of standard tuberculosis treatment to be EUR 7363.99. For this reason, case files were requested for insurance claims involving LTBI and treatment costs of EUR 7000.00 or more. These were analysed manually in relation to a progression.

For an LTBI to be recognised as an occupational disease, different requirements need to be fulfilled. The LTBI must be confirmed by a positive Interferon Gamm Release Assay (IGRA) and TB must be excluded by chest X-ray. In addition, an occupational exposure must be known. As HW with regular contact to infectious patients are examined every year or every third year and all other HW are examined after contact to an infectious patient or infectious materials, the assessment of the occupational exposure is seldom a problem.

We also conducted a retrospective survey in December 2019 to study both the progression rate and the use of TPT among HW. Workers insured by BGW with an LTBI recognised as an occupational disease between 2009 and 2018 were invited to participate in the survey. The participants received a standardised questionnaire to complete themselves. We wrote to a total of 1709 insured patients. Due to incorrect addresses, 349 insured persons (20.4%) could not be contacted. The questionnaire was returned by 732 persons, the adjusted response rate was 53.8%. Data analysis comprised 575 questionnaires (78.6%). We exclude 149 questionnaires (20.4%) due to implausible responses. Moreover, questionnaires were completed by eight relatives for deceased insured patients (1.1%) and by one relative for an insured patient with dementia. Because the relatives did not provide complete information, these eight questionnaires were also excluded from the analysis.

The questionnaire was developed for the study and reviewed in a pre-test with ten test subjects to ensure that it was understandable. The questionnaire contained sociodemographic questions, as well as questions about the diagnosis of the LTBI, TPT, and the development of active TB. For continuous variables, the mean value was calculated with the standard deviation (SD) and the interquartile range (IQR). Categorical variables were expressed as absolute and relative frequencies. Binary logistic regression with the use of TPT as a target value was used to study influencing factors. Odds ratios (OR), the 95% confidence intervals and p-values were also calculated. The respondents’ professions were grouped into physicians, activities primarily involving patient contact (e.g., nurses) and activities with little or no patient contact (e.g., domestic services staff). The data analysis was performed using SPSS version 26 (IBM Corp., Armonk, NY, USA). The significance level was set at 5%.

3. Results

For the questionnaire analysis, 575 insured patients were eligible for inclusion, which represented 42.3% of all insured patients who received a questionnaire. The study population predominantly consisted of women (82.6%), aged 46.4 years old on average at the probable time of infection (SD 11.1; IQR 16.0). The observation time after diagnosis of an LTBI was one to three years in 32.2% of cases, four to six years in 32.5% of cases, and seven to twelve years in 35.3% of cases. The majority of respondents (62.8%) were working in a hospital at the time of exposure. Respondents were most frequently employed in healthcare and nursing (42.4%). The LTBI was diagnosed for most respondents by company physicians (57.5%) (Table 2).

One-third (33.2%) of survey respondents reported having undergone TPT (Table 3). The most common treatment method was isoniazid over a period of nine months (45.0%). Shorter treatment regimens using rifampicin were performed rarely; rifampicin was mostly administered in combination with isoniazid (3.7%). The most common reason given for use of therapy was an existing immunodeficiency (10.6%). Other reasons stated were autoimmune and tumor-related diseases as well as kidney diseases requiring dialysis.

The use of TPT was dependent on age (Table 4). In the under-30 age group, 52.7% reported having undergone TPT. In the 40–49 and 50–59 age groups, use of TPT was significantly lower at 34.6% and 24.9% respectively. Compared to physicians, health workers in activities primarily involving patient contact (OR 2.6 (95% CI: 1.3 to 5.0)) and
health workers in activities with little or no patient contact (OR 3.1 (95% CI: 1.6 to 6.3)) more frequently underwent TPT. The year of diagnosis, gender, and reason for screening all had no significant impact on the use of TPT (Table 4).

A total of six insured patients with progressive cases were identified (Table 5). No progressive cases were found by means of LTBI/TB pairing in the BGW occupational disease routine database. Treatment costs exceeding EUR 7000 were incurred in 16 cases, three of which we identified as progressive cases. Table 5 provides a description of these three cases. The remaining high-cost LTBI cases were not related to progression to TB.

In the survey, another three insured patients reported an LTBI progressing to active TB (Table 6). The three progressive cases were women who worked in different medical fields at the time of infection. All of them had undergone TPT, and two of them had risk factors for progressive LTBI. For two cases, the time between the LTBI and TB diagnosis was less than one year; and for the third person there were two years between the LTBI and TB diagnoses.

Table 2. Description of the study population from the survey ($n = 575$).

| Characteristic | n   | %   |
|---------------|-----|-----|
| Gender        |     |     |
| Women         | 475 | 82.6|
| Men           | 100 | 17.4|
| Age groups at time of diagnosis |     |     |
| Under 30      | 55  | 9.6 |
| 30–39         | 91  | 15.8|
| 40–49         | 162 | 28.2|
| 50–59         | 209 | 36.3|
| ≥60           | 58  | 10.1|
| Duration of observation, grouped |     |     |
| 1–3 years     | 185 | 32.2|
| 4–6 years     | 187 | 32.5|
| 7–12 years    | 203 | 35.3|
| Occupational field at time of tuberculosis exposure |     |     |
| Hospital 1    | 361 | 62.8|
| Dental/medical practice | 82  | 14.3|
| Inpatient, outpatient care services | 67  | 11.7|
| Social and advisory services | 36  | 6.3 |
| Laboratories  | 9   | 1.6 |
| Other 2       | 20  | 3.5 |
| Occupation at time of tuberculosis exposure |     |     |
| Healthcare and nursing specialist | 244 | 42.4|
| Physician     | 82  | 14.3|
| Specialist medical assistant | 77  | 13.4|
| Specialist medical technical assistant | 39  | 6.8 |
| Nursing assistant | 30  | 5.2 |
| Geriatric nurse | 24  | 4.2 |
| Social work   | 23  | 4.0 |
| Other 3       | 56  | 9.7 |
| Reason for tuberculosis screening |     |     |
| Preventive check-up company physician | 325 | 56.5|
| Screening public health authority | 185 | 32.2|
| Other 4       | 65  | 11.3|

1 Including rehabilitation clinics. 2 Dialysis facility, public health authority, pathology, psychiatric institution, school, administrative institution, no response. 3 Trainee, occupational therapist, hairdresser, domestic services staff, remedial therapist, managerial function, teacher, patient support service, physiotherapist, psychologist, autopsy technician. 4 Assignment abroad, intention to receive BCG vaccination, clinical symptoms, needlestick injury, rheumatism diagnosis, routine examination as required by the Ordinance on Preventive Occupational Medicine, study participation, examination by regular general practitioner, elective precautionary measure.
Table 3. Information provided on TPT (n = 191; 33.2%) from survey.

| TPT Characteristic                        | n   | %   |
|-------------------------------------------|-----|-----|
| Treatment regimen                         |     |     |
| Isoniazid, 6 months                       | 68  | 35.6|
| Isoniazid, 9 months                       | 86  | 45.0|
| Isoniazid, rifampicin, 3 months           | 7   | 3.7 |
| Other 1                                   | 23  | 12.0|
| Unknown (drug or time period)             | 7   | 3.7 |
| Reasons stated for undergoing TPT 2       |     |     |
| Immunodeficiency                          | 19  | 10.6|
| Rheumatism treatment                      | 6   | 3.4 |
| Kidney disease/dialysis                   | 1   | 0.6 |
| Tumours                                  | 2   | 1.1 |
| (Planned) pregnancy                      | 5   | 2.8 |
| Other reason 3                            | 26  | 14.5|
| Unknown                                  | 120 | 67.0|
| Reasons stated against use of TPT 2,4    |     |     |
| Aged over 50                              | 102 | 20.3|
| No immunodeficiency                      | 203 | 40.4|
| Unknown time of infection                 | 62  | 12.3|
| Existing liver disease                    | 7   | 1.4 |
| Other reason 5                            | 48  | 9.5 |
| Unknown                                  | 81  | 16.1|

1 Isoniazid, 3 months; isoniaizid, 4 months; isoniaizid, 12 months; isoniaizid and rifampicin, 4 months; isoniaizid and rifampicin, 6 months; rifampicin, 4 months; rifampicin, 6 months. 2 Multiple responses possible. 3 Young age, underlying disease (of lungs), therapy recommended by public health authority or attending physician. 4 Reference value in this case: n = 384. 5 Personal rejection, (planned) pregnancy, no therapy recommendation expressed by public health authority or attending physician, drug allergy or expected side effects, multi-resistant pathogen in carrier.

Table 4. Factors influencing the use of TPT from the surveys (n = 575).

| Influencing Factors                           | n   | TPT | % Yes (**) | OR (95% Confidence Interval) |
|----------------------------------------------|-----|-----|------------|-----------------------------|
| Year of diagnosis                            |     | Yes | No         |                             |
| 2016–2018                                    | 184 | 59  | 125        | 32.1                        |
| 2013–2015                                    | 188 | 59  | 129        | 31.4 0.9 (0.6–1.4)          |
| Before 2013                                  | 203 | 73  | 130        | 36.0 1.2 (0.7–1.8)          |
| Gender                                       |     |     |            |                             |
| Female                                       | 475 | 162 | 313        | 34.1                        |
| Male                                         | 100 | 29  | 71         | 29.0 1.1 (0.7–1.9)          |
| Age upon infection                           |     |     |            |                             |
| Under 30                                     | 55  | 29  | 26         | 52.7                        |
| 40–49 years                                  | 162 | 56  | 106        | 34.6 0.5 * (0.3–0.9)        |
| 50–59 years                                  | 209 | 52  | 157        | 24.9 0.3 * (0.2–0.6)        |
| Over 60                                      | 58  | 19  | 39         | 32.8 0.5 (0.2–1.1)          |
| Activity                                     |     |     |            |                             |
| Physician                                    | 82  | 15  | 67         | 18.3                        |
| Activity involving patient contact           | 312 | 105 | 207        | 33.7 2.6 * (1.3–5.0)        |
| Activity with little or no patient contact    | 181 | 71  | 110        | 39.2 3.1 * (1.6–6.3)        |
| Reason for screening                         |     |     |            |                             |
| Preventive check-up by company doc           | 325 | 103 | 222        | 31.7                        |
| Screening by public health authority         | 185 | 63  | 122        | 34.1 1.0 (0.7–1.5)          |
| Other                                        | 65  | 40  | 25         | 61.5 1.3 (0.7–2.3)          |

* Significant. (**) Expressed as row percentage.
Table 5. Case summary of progressive cases based on file analysis.

| Case 1 | Case 2 | Case 3 |
|--------|--------|--------|
| Age at time of LTBI diagnosis | 51 years | 24 years | 39 years |
| Gender | Female | Male | Female |
| Activity | Inpatient care | Homelessness assistance | Outpatient care |
| TPT | Yes | Yes | Rejected by patient |
| Indication for TPT | Immunosuppressant medications | Recommended due to young age | Unknown |
| TPT regime | Isoniazid/9 months | Isoniazid/6 months | Isoniazid/6 months |
| Progression after | Three years | Eighteen months | Ten months |

Table 6. Case summary of progressive cases based on survey.

| Case 1 | Case 2 | Case 3 |
|--------|--------|--------|
| Age at time of diagnosis | 52 years | 28 years | 27 years |
| Gender | Female | Female | Female |
| Activity | Inpatient care | Medical technical assistant | Specialist medical assistant |
| TPT | Yes | Yes | Yes |
| Indication for TPT | Rheumatic diseases | Immunodeficiency | Unknown |
| Treatment regime | Isoniazid/9 months | Isoniazid/6 months | Isoniazid/6 months |
| Progression after | Two years | <one year | <one year |

The cumulative TB incidence in the retrospective survey cohort was 0.52% (95% CI: 0.14% to 1.65%) (Table 7). Taking into account the time at risk totaling 3080 person years, the incidence was 0.97 cases per 1000 person years (95% CI: 0.25% to 3.10%).

Table 7. Observation period and progression rate among 575 workers with occupational LTBI with code 3101 from the survey.

| n | Observation Period in Years | TB | Cumulative Incidence (95% CI) | Incidence per 1000 Person Years (95% CI) |
|---|-----------------------------|----|-------------------------------|----------------------------------------|
| 575 | Mean | 5.4 | 2.8 | 5.0 | 5.0 | 3 | 0.52% | (0.14%–1.65%) | 0.97 | (0.25–3.10) |

4. Discussion

The data presented here describe, for the first time, the annual progression rate from LTBI to active TB and the use of TPT among HW in Germany. One-third of HW with LTBI underwent TPT. The most common indication reported by the insured patients for TPT was immunodeficiency, so treatment seems to be conducted on the basis of risk. Within the overall cohort of 1711 health workers who had received recognition of LTBI as an occupational disease between 2009 and 2018, we identified six HW whose LTBI was progressive (0.4%). For the HW subgroup that participated in the survey (making it the most valid available dataset), the cumulative incidence of progression was lower than generally expected at 0.52%. The incidence density was one case per 1000 person years.
Compared to the general population with an estimated progression rate of around 5 to 10% within the first two years of infection, our study shows a lower risk of progression [6]. One possible explanation is the “healthy worker” effect, and the lower occurrence that this entails of risk factors that favour progression, such as alcoholism, nicotine consumption or intravenous drug use [11,14,15]. The reason for performing the diagnosis was an examination by a company physician in the majority of cases (56.5%). In addition to occupational check-ups (as required by the Ordinance on Preventive Occupational Medicine) following TB contact, examinations by company physicians may also be conducted in connection with new employment or in mandatory regular examinations due to the occupational risk that arises from the care and treatment of patients with tuberculosis. This means that some infections from further in the past might have been identified that already had a low progression risk at the time of diagnosis.

Results from the USA and Canada regarding the use of TPT are inconsistent and range from 20 to 80% [16–18]. In our study, one-third of the participants underwent TPT. As in previous studies, the use of TPT varied between physicians, HW in activities primarily involving patient contact, and HW in activities with little or no patient contact [9,19]. The medical training and knowledge of HW, for example, regarding side effects, may be a factor potentially discouraging them from undergoing TPT. Moreover, TPT is not recommended in Germany for patients aged 50 or over [8]. It is noteworthy that only one third of the participants answered questions concerning reason for and against TPT (Table 3). This might be because they were not well aware of the pros and cons of TPT. Therefore, better information about progression risk and indications for TPT for HW seem warranted.

In the USA, the guidelines on the testing, screening and treatment of TB were updated in 2019. Health workers with a diagnosed LTBI are recommended to undergo TPT, unless there are prior contraindications (such as previous LTBI treatment) [20]. Our study suggests that the progression rate for health workers is likely to be low. It thus seems advisable to define case-specific indications for TPT. However, further studies are needed to support this conclusion.

Although five cases progressed to active TB despite TPT, this remains an effective method of mitigating the risk of progression. It should therefore be assumed that the progression rate would have been higher without the use of TPT in this study population. Our data show that risk groups should continue to be observed even after TPT.

In terms of limitations, it should be noted that it was impossible to verify the results due to the anonymous nature of the survey. Moreover, the progression risk may be underestimated by non-participation in the survey or the early death of TB patients. Given the generally low mortality of TB patients in Germany, however, the latter is considered to be unlikely [21]. There is also the possibility that insured patients have not reported active TB progression to the BGW. In addition, we know the reporting date of the LTBI, but not the infection period. Where infections occurred further in the past, it is possible that progressive cases were not identified by our study, which may also have led to underestimation of the progression rate.

It should be borne in mind that TB is not the only occupational risk for HW. COVID-19 made evident how vulnerable HW are worldwide and in Germany [22,23]. Blood-borne virus infections are another risk. However, prevention, safe instruments, vaccination and new treatments helped to reduce the risk for HW [24]. Besides infections, skin diseases and low back pain are other prevalent work-related diseases in HW, which warrant prevention and health promotion [25].

5. Conclusions

The occupational check-ups offered for health workers following contact with TB patients in low-incidence countries such as Germany are an important instrument for TB prevention in healthcare. They ensure that health workers are informed about the risks of TB infection and enable the early detection of TB. Following our data, it seems warranted to better inform HW about the option and the benefit–risk profile of TPT. As most HW who
progressed from LTBI to active TB had medical risk factors for TB, the administration of TPT seems most needed in HW with pre-existing health problems.

**Author Contributions:** Conceptualization, A.N., H.Z. and J.S.; methodology, N.Z., J.F.K., A.N. and J.S.; software, N.Z.; validation, J.S. and H.Z.; formal analysis, N.Z., J.F.K. and A.N.; investigation, N.Z.; data curation, N.Z.; writing—original draft preparation, N.Z.; writing—review and editing, A.N., J.F.K., H.Z. and J.S.; supervision, A.N.; project administration, N.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with German data protection regulations. The data protection protocol of the study was drafted following consultation by the data protection responsible for the BGW. Ethical review and approval were waived for this study, due to the study using pre-existing routine data of insurance and anonymous questionnaire data. Following German regulations, no evaluation by an ethics commission was needed. The study was conducted according to the guidelines of the Declaration of Helsinki.

**Informed Consent Statement:** The participants were informed about the purpose of the study. The return of the anonymous questionnaire was interpreted as implicit consent to participate.

**Data Availability Statement:** Data of the study are available upon request by the authors.

**Acknowledgments:** We thank the Health Workers for their participation in the study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hermes, L.; Kersten, J.F.; Nienhaus, A.; Schablon, A. Risk Analysis of Latent Tuberculosis Infection among Health Workers Compared to Employees in Other Sectors. *Int. J. Environ. Res. Public Health* **2020**, *17*, 4643. [CrossRef]

2. Schablon, A.; Nienhaus, A. Prävalenz und Inzidenz latenten Tuberkuloseinfektionen bei Beschäftigten im Gesundheitswesen–Ergebnisse aus zehn Jahren Betriebsärztenetzwerk. In *Tuberkulose als Berufskrankheit*; Nienhaus, A., Brandenburg, S., Teschler, H., Eds.; Ecomed Medizin: Landsberg am Lech, Germany, 2017; pp. 213–224.

3. Nienhaus, A.; Schablon, A.; Preisser, A.M.; Ringshausen, F.C.; Diel, R. Tuberculosis in healthcare workers—A narrative review from a German perspective. *J. Occup. Med. Toxicol.* **2014**, *9*, 9. [CrossRef]

4. Brandenburg, S.; Woltjen, M. Rechtliche Voraussetzungen für die Anerkennung und Entschädigung der Tuberkulose als Berufskrankheit. In *Tuberkulose als Berufskrankheit*; Nienhaus, A., Brandenburg, S., Teschler, H., Eds.; Ecomed Medizin: Landsberg am Lech, Germany, 2017; pp. 91–98.

5. Dulan, M.; Wendeler, D.; Nienhaus, A. Berufsgleitende Infektionskrankheiten bei Beschäftigten im Gesundheitsdienst 2017. *Zent. Für Arb. Arb. Ergon.* **2019**, *69*, 16–22. [CrossRef]

6. Diel, R.; Loytved, G.; Nienhaus, A.; Castell, S.; Detjen, A.; Geerdes-Fenge, H.; Haas, W.; Hauer, B.; Königstein, B.; Maffei, D.; et al. Neue Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose. *Pneumologie* **2011**, *65*, 359–378. [CrossRef]

7. Smieja, M.; Marchetti, C.A.; Cook, D.J.; Smaill, F.M. Isoniazid for preventing tuberculosis in non-HIV infected persons. *Cochrane Database Syst. Rev.* **2000**, *1999*, CD001363. [CrossRef] [PubMed]

8. Schaberg, T.; Bauer, T.; Brinkmann, F.; Diel, R.; Feiterna-Sperling, C.; Haas, W.; Hartmann, P.; Hauer, B.; Heyckendorf, J.; Lange, C.; et al. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. *Pneumologie* **2017**, *71*, 325–397. [CrossRef] [PubMed]

9. Gershon, A.S.; McGee, A.; Bayoumi, A.M.; Raboud, J.; Yang, J. Health Care Workers and the Initiation of Treatment for Latent Tuberculosis Infection. *Clin. Infect. Dis.* **2004**, *39*, 667–672. [CrossRef]

10. Schablon, A.; Nienhaus, A.; Ringshausen, F.C.; Preisser, A.; Peters, C. Occupational screening for tuberculosis and use of a borderline zone for interpretation of the IGRA in German healthcare workers. *PLoS ONE* **2014**, *9*, e115322. [CrossRef] [PubMed]

11. Herzmann, C.; Sotgiu, G.; Bellinger, O.; Diel, R.; Gerdes, S.; Goetsch, U.; Heykes-Uden, H.; Schaberg, T.; Lange, C.; TB or not TB Consortium. Risk for latent and active tuberculosis in Germany. *Infection* **2017**, *45*, 283–290. [CrossRef]

12. Teschler, H.; Nienhaus, A., Brandenburg, S., Castell, S., Eds.; Ecomed Medizin: Landsberg am Lech, Germany, 2017; pp. 213–224.

13. Schablon, A.; Nienhaus, A.; Ringshausen, F.C.; Preisser, A.; Peters, C. Occupational screening for tuberculosis and use of a borderline zone for interpretation of the IGRA in German healthcare workers. *PLoS ONE* **2014**, *9*, e115322. [CrossRef] [PubMed]

14. Gershon, A.S.; McGee, A.; Bayoumi, A.M.; Raboud, J.; Yang, J. Health Care Workers and the Initiation of Treatment for Latent Tuberculosis Infection. *Clin. Infect. Dis.* **2004**, *39*, 667–672. [CrossRef]

15. Schablon, A.; Nienhaus, A.; Ringshausen, F.C.; Preisser, A.; Peters, C. Occupational screening for tuberculosis and use of a borderline zone for interpretation of the IGRA in German healthcare workers. *PLoS ONE* **2014**, *9*, e115322. [CrossRef] [PubMed]

16. Arguelles Perez, E.; Sea, S.K.; Schneider, W.J.; Eisenstein, C.; Brown, A.E. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center. *Clin. Infect. Dis.* **2017**, *65*, 2105–2111. [CrossRef]

17. Xu, Y.; Schwartzman, K. Referrals for positive tuberculin tests in new health care workers and students: A retrospective cohort study. *BMC Public Health* **2010**, *10*. [CrossRef]
18. Proops, D.C.; Knorr, J.A.; Meissner, J.S.; Kreiswirth, B.N.; Ahuja, S.D. Epidemiology of tuberculosis among healthcare personnel in New York City. *Int. J. Tuberc. Lung. Dis.* 2020, 24, 619–625. [CrossRef] [PubMed]

19. Lee, H.; Koo, G.; Min, J.H.; Sun Park, T.; Won Park, D.; Moon, J.Y.; Kim, S.H.; Kim, T.H.; Yoon, H.J.; Won Sohn, J. Factors associated with non-initiation of latent tuberculosis treatment among healthcare workers with a positive interferon-gamma releasing assay. *Sci. Rep.* 2019, 9, 61. [CrossRef] [PubMed]

20. Sosa, L.E.; Njie, G.J.; Lobato, M.N.; Morris, S.B.; Buchta, W.; Casey, M.L.; Goswami, N.D.; Gruden, M.A.; Hurst, B.J.; Khan, A.R.; et al. Tuberculosis Screening, Testing and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC. *Morb. Mortal. Wkly. Rep.* 2019, 68, 439–443. [CrossRef]

21. Robert Koch-Institut. Eckdaten zur Tuberkulose in Deutschland für das Jahr 2018. *Epidemiol. Bull.* 2020, 11, 6–7.

22. Gholamia, M.; Fawada, I.; Shadana, S.; Rowaieea, R.; Ghanema, H.A.; Khamisb, A.H.; Hoa, S.B. COVID-19 and healthcare workers: A systematic review and meta-analysis. *Int. J. Infect. Dis.* 2021, 104, 335–346. [CrossRef]

23. Nienhaus, A.; Hod, R. COVID-19 among Health Workers in Germany and Malaysia. *Int. J. Environ. Res. Public Health* 2020, 17, 4881. [CrossRef] [PubMed]

24. Nienhaus, A. Infections in Healthcare Workers in Germany—22 Year Time Trends. *Int. J. Environ. Res. Public Health* 2018, 15, 2656. [CrossRef] [PubMed]

25. Schröder, C.; Nienhaus, A. Intervertebral Disc Disease of the Lumbar Spine in Health Personnel with Occupational Exposure to Patient Handling—A Systematic Literature Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2020, 17, 4832. [CrossRef] [PubMed]